Stay updated with breaking news from Mcelu. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Celularity Inc. (NASDAQ:CELU – Get Rating) was the recipient of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 5,170,000 shares, a growth of 8.8% from the March 15th total of 4,750,000 shares. Approximately 7.4% of the company’s shares are short sold. Based on […]
Celularity Inc. (NASDAQ:CELU – Get Rating) was the target of a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 4,750,000 shares, a growth of 38.1% from the February 28th total of 3,440,000 shares. Currently, 9.2% of the company’s shares are sold short. Based on […]
Celularity (NASDAQ:CELU – Get Rating) and Kezar Life Sciences (NASDAQ:KZR – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, institutional ownership, dividends, profitability and earnings. Valuation and Earnings This table compares Celularity and Kezar […]
Equities research analysts expect Celularity Inc. (NASDAQ:CELU – Get Rating) to post earnings of ($0.23) per share for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Celularity’s earnings, with the highest EPS estimate coming in at ($0.11) and the lowest estimate coming in at ($0.29). The company is scheduled to […]
Zacks Investment Research lowered shares of Celularity (NASDAQ:CELU – Get Rating) from a buy rating to a hold rating in a report published on Monday, Zacks.com reports. According to Zacks, “Celularity Inc. is a clinical stage biotechnology company. It involved in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies, including unmodified NK cells, genetically-modified […]